Microbot Medical Inc. (NASDAQ:MBOT) Receives Average Rating of “Moderate Buy” from Analysts

Microbot Medical Inc. (NASDAQ:MBOT) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.6250.

Several research firms have recently commented on MBOT. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Microbot Medical in a report on Tuesday, April 14th. Wall Street Zen upgraded Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Loop Capital set a $4.00 price objective on Microbot Medical in a research report on Wednesday, June 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MBOT. CIBC Bancorp USA Inc. purchased a new position in shares of Microbot Medical during the third quarter valued at about $4,435,000. Heights Capital Management Inc. bought a new position in shares of Microbot Medical in the 3rd quarter valued at about $2,693,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Microbot Medical by 137.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,454,000 shares of the biotechnology company’s stock valued at $4,435,000 after acquiring an additional 842,000 shares during the last quarter. DNB Asset Management AS lifted its holdings in shares of Microbot Medical by 178.1% in the 4th quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock valued at $1,355,000 after acquiring an additional 433,869 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Microbot Medical by 14.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock valued at $7,148,000 after acquiring an additional 292,923 shares during the last quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Stock Performance

Shares of MBOT opened at $1.78 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 22.59 and a quick ratio of 21.93. Microbot Medical has a 1 year low of $1.60 and a 1 year high of $4.67. The company has a 50 day simple moving average of $2.07 and a two-hundred day simple moving average of $2.18. The firm has a market cap of $119.56 million, a P/E ratio of -6.85 and a beta of 1.04.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, equities analysts expect that Microbot Medical will post -0.31 earnings per share for the current fiscal year.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.